Patent classifications
A61P15/16
Isoindolone derivatives
The present invention provides for compounds of formula (I) ##STR00001##
wherein A, Y, J, R.sup.1, R.sup.2, and R.sup.3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.
Salt of fused heterocyclic derivative and crystal thereof
The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.
Modulators of sperm hypermotility and uses thereof
The invention provides novel compositions and compounds that inhibit CatSper channel activity, that preferentially inhibits sperm hyperactivity over sperm motility, or both. The compounds of the invention are useful as contraceptive agents that may be adminstered to males, females, or concurrently to both sexual partners. The invention further provides methods of conducting drug discovery business and of conducting a reproductive medicine business. The invention also provides methods of identifying compounds that modulate sperm hypermotility.
Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.
Nonhormonal Unisex Contraceptives
Nonhormonal unisex contraceptive products, compositions, formulations and methods of use comprise an effective amount of a targeted mild mitochondria uncoupler.
Nonhormonal Unisex Contraceptives
Nonhormonal unisex contraceptive products, compositions, formulations and methods of use comprise an effective amount of a targeted mild mitochondria uncoupler.
Selective androgen receptor modulators (SARMs) and uses thereof
Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions. ##STR00001##
COMPOSITIONS AND METHODS FOR SUSTAINED DRUG RELEASE FROM AN INJECTABLE HYDROGEL
Compositions, devices and methods of using one or more hydrogel for contraception as well as localized, sustained delivery of drugs are disclosed. Device (e.g., hydrogel) embodiments are easily injectable, have a quick gelation rate, are highly durable, and are capable of lasting greater than 3 months in vivo. The devices/hydrogel may be used for occlusion of a bodily duct, such as the vas deferens and/or fallopian tubes, for male and female contraception, respectively. Once implanted, the device/hydrogel is able to release one or more drugs, such as small molecules or biologics, indirectly, systemically, and/or directly to the site of interest over a sustained period of time, such as for prevention and/or treatment of STIs.
COMPOSITIONS AND METHODS FOR SUSTAINED DRUG RELEASE FROM AN INJECTABLE HYDROGEL
Compositions, devices and methods of using one or more hydrogel for contraception as well as localized, sustained delivery of drugs are disclosed. Device (e.g., hydrogel) embodiments are easily injectable, have a quick gelation rate, are highly durable, and are capable of lasting greater than 3 months in vivo. The devices/hydrogel may be used for occlusion of a bodily duct, such as the vas deferens and/or fallopian tubes, for male and female contraception, respectively. Once implanted, the device/hydrogel is able to release one or more drugs, such as small molecules or biologics, indirectly, systemically, and/or directly to the site of interest over a sustained period of time, such as for prevention and/or treatment of STIs.
Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
The present disclosure relates to compositions and methods for inhibiting inflammation and reducing the risk of spreading sexually transmitted diseases using an alginic acid-based antimicrobial compound. Such compositions provide dual protection by (1) attacking and inactivating viruses and other microbes and (2) blocking the host response that viruses trigger to invade host cells. Such compositions can also be part of an acid buffering contraceptive.